$TAK

Platford Giles Richard sold $532K of TAK

Platford Giles Richard (President, IBU) sold 31,083 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.53M total) on 2026-08-10.

Original reporting
SEC EDGAR · Platford Giles Richard
Published Aug 13, 2026, 1:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

An officer (President, IBU) conducted an open-market sale of 31,083 shares at $17.10, totaling about $531.5k, with holdings after the trade of 315,838 shares.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no accompanying fundamental or regulatory catalyst in the text.

03

What to watch

The article lacks context on total holdings, prior sale frequency, and whether other insiders or executives made offsetting purchases.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12 for a sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd (TAK).

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda’s Form 4 shows insider Platford Giles Richard sold 31,083 shares at $17.10 on 2026-08-10.

Expected impact

Likely limited near-term impact; treat as low-signal unless repeated or paired with other disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but insider sales alone typically have weak causal linkage to fundamentals, and the article provides no new operational or guidance catalyst.

Market effects

No sector read-through is provided beyond a single insider transaction at a large pharma company.

None indicated.

None indicated.

Counterpoint

The sale may be liquidity-driven (taxes, diversification) and the absence of a 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • TAK

    Takeda Pharmaceutical Co Ltd, the Form 4 issuer.

  • Platford Giles Richard

    President, IBU, who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.